Literature DB >> 29446003

Development of a 'ready-to-use' tool that includes preventability, for the assessment of adverse drug events in oncology.

Guillaume Hébert1,2, Florence Netzer3, Sylvain Landry Kouakou3, François Lemare3,4,5, Etienne Minvielle6,4.   

Abstract

Background Adverse drug events (ADEs) occur frequently in oncology and justify continuous assessment and monitoring. There are several methods for detecting them, but the trigger tool method seems the most appropriate. Although a generic tool exists, its use for ADEs in oncology has not been convincing. The development of a focused version is therefore necessary. Objective To provide an oncology-focused trigger tool that evaluates the prevalence, harm, and preventability in a standardised method for pragmatic use in ADE surveillance. Setting Hospitals with cancer care in France. Method The tool has been constructed in two steps: (1) constitution of an oncology-centred list of ADEs; 30 pharmacists/practitioners in cancer care from nine hospitals selected a list of ADEs using a method of agreement adapted from the RAND/UCLA Appropriateness Method; and (2) construction of three standardised dimensions for the characterisation of each ADE (including causality, severity, and preventability). Main outcome measure The main outcome measure was validation of the tool, including preventability criteria. Results The tool is composed of a final list of 15 ADEs. For each ADE, a 'reviewer form' has been designed and validated by the panel. It comprises (1) the trigger(s), (2) flowcharts to guide the reviewer, (3) criteria for grading harm, and (4) a standardised assessment of preventability with 6-14 closed sentences for each ADE in terms of therapeutic management and/or prevention of side-effects. Conclusion A complete 'ready-to-use' tool for ADE monitoring in oncology has been developed that allows the assessment of three standardised dimensions.

Entities:  

Keywords:  Adverse drug event; France; Healthcare quality; Oncology; Patient cancer care; Preventability; Trigger tool

Mesh:

Substances:

Year:  2018        PMID: 29446003     DOI: 10.1007/s11096-017-0542-3

Source DB:  PubMed          Journal:  Int J Clin Pharm


  42 in total

1.  Patient-specific risk factors of adverse drug events in adult inpatients - evidence detected using the Global Trigger Tool method.

Authors:  Marja Härkänen; Marjo Kervinen; Jouni Ahonen; Ari Voutilainen; Hannele Turunen; Katri Vehviläinen-Julkunen
Journal:  J Clin Nurs       Date:  2014-11-13       Impact factor: 3.036

2.  Surveillance for quality assessment: IV. Surveillance using a hospital information system.

Authors:  D C Classen; J P Burke; S L Pestotnik; R S Evans; L E Stevens
Journal:  Infect Control Hosp Epidemiol       Date:  1991-04       Impact factor: 3.254

3.  Performance of the adverse drug event trigger tool and the global trigger tool for identifying adverse drug events: experience in a Belgian hospital.

Authors:  Lise Carnevali; Bruno Krug; Fabienne Amant; Dominique Van Pee; Véronique Gérard; Xavier de Béthune; Anne Spinewine
Journal:  Ann Pharmacother       Date:  2013-11       Impact factor: 3.154

4.  How to decide whether a clinical practice guideline is trustworthy.

Authors:  David F Ransohoff; Michael Pignone; Harold C Sox
Journal:  JAMA       Date:  2013-01-09       Impact factor: 56.272

5.  Safety hazards in cancer care: findings using three different methods.

Authors:  Henriette Lipczak; Janne Lehmann Knudsen; Aase Nissen
Journal:  BMJ Qual Saf       Date:  2011-06-28       Impact factor: 7.035

6.  Consensus building for development of outpatient adverse drug event triggers.

Authors:  Hillary J Mull; Jonathan R Nebeker; Stephanie L Shimada; Haytham M A Kaafarani; Peter E Rivard; Amy K Rosen
Journal:  J Patient Saf       Date:  2011-06       Impact factor: 2.844

7.  Evaluating iatrogenic prescribing: development of an oncology-focused trigger tool.

Authors:  Guillaume Hébert; Florence Netzer; Marie Ferrua; Michel Ducreux; François Lemare; Etienne Minvielle
Journal:  Eur J Cancer       Date:  2014-12-27       Impact factor: 9.162

8.  Assessment of the global trigger tool to measure, monitor and evaluate patient safety in cancer patients: reliability concerns are raised.

Authors:  Thea Otto Mattsson; Janne Lehmann Knudsen; Jens Lauritsen; Kim Brixen; Jørn Herrstedt
Journal:  BMJ Qual Saf       Date:  2013-02-27       Impact factor: 7.035

9.  Comparison of three methods for estimating rates of adverse events and rates of preventable adverse events in acute care hospitals.

Authors:  Philippe Michel; Jean Luc Quenon; Anne Marie de Sarasqueta; Olivier Scemama
Journal:  BMJ       Date:  2004-01-24

10.  Adverse drug events in older hospitalized patients: results and reliability of a comprehensive and structured identification strategy.

Authors:  Joanna E Klopotowska; Peter C Wierenga; Clementine C M Stuijt; Lambertus Arisz; Marcel G W Dijkgraaf; Paul F M Kuks; Henk Asscheman; Sophia E de Rooij; Loraine Lie-A-Huen; Susanne M Smorenburg
Journal:  PLoS One       Date:  2013-08-05       Impact factor: 3.240

View more
  2 in total

1.  Association between cancer-specific adverse event triggers and mortality: A validation study.

Authors:  Saul N Weingart; Jason Nelson; Benjamin Koethe; Omar Yaghi; Stephan Dunning; Albert Feldman; David Kent; Allison Lipitz-Snyderman
Journal:  Cancer Med       Date:  2020-04-13       Impact factor: 4.452

2.  Developing a cancer-specific trigger tool to identify treatment-related adverse events using administrative data.

Authors:  Saul N Weingart; Jason Nelson; Benjamin Koethe; Omar Yaghi; Stephan Dunning; Albert Feldman; David M Kent; Allison Lipitz-Snyderman
Journal:  Cancer Med       Date:  2020-01-03       Impact factor: 4.452

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.